Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer. [electronic resource]
Producer: 20141021Description: e1227 p. digitalISSN:- 2041-4889
- Animals
- Antineoplastic Agents -- pharmacology
- Apoptosis -- drug effects
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Cell Cycle Checkpoints -- drug effects
- Cell Line, Tumor
- Cell Movement -- drug effects
- Cyclin B1 -- genetics
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Drug Resistance, Neoplasm
- Epithelial-Mesenchymal Transition -- drug effects
- Gefitinib
- HEK293 Cells
- Humans
- Kaplan-Meier Estimate
- Lung Neoplasms -- drug therapy
- Mice
- Mice, Nude
- MicroRNAs -- metabolism
- Neoplasm Invasiveness
- Protein Kinase Inhibitors -- pharmacology
- Proto-Oncogene Proteins -- genetics
- Quinazolines -- pharmacology
- RNA Interference
- Receptor Protein-Tyrosine Kinases -- metabolism
- Time Factors
- Transfection
- Tumor Burden -- drug effects
- Wnt Proteins -- genetics
- Wnt-5a Protein
- Xenograft Model Antitumor Assays
- Axl Receptor Tyrosine Kinase
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.